Complementary actions of finerenone and <scp>SGLT2</scp> ‐i on renal outcomes?: An urgent need for more information-Reference-Cited by-同舟云学术

Complementary actions of finerenone and SGLT2 ‐i on renal outcomes?: An urgent need for more information

Published:2022-10-22 Issue:12 Volume:27 Page:915-916
ISSN:1320-5358
Container-title:Nephrology
language:en
Short-container-title:Nephrology

Author:

Rebelos Eleni¹²^ORCID,Tentolouris Nikolaos³

Affiliation:

1. Turku PET Centre University of Turku Turku Finland

2. Institute of Clinical Physiology National Research Council (CNR) Pisa Italy

3. 1st Department of Propaedeutic and Internal Medicine, Medical School National and Kapodistrian University of Athens, Laiko General Hospital Athens Greece

Publisher

Wiley

Subject

Nephrology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nep.14124

Reference7 articles.

1. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial

2. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

3. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage

4. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal Perfusion, Oxygenation and Metabolism: The Role of Imaging;Journal of Clinical Medicine;2023-08-06

2. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone;Expert Review of Clinical Pharmacology;2023-05-23